Despite a growing number of clinical and real-world studies, there has been no direct comparison between the two anti-GD2 antibodies DB (±IL-2) and NAXI (+GM-CSF) in patients with relapsed/refractory neuroblastoma. The gene discussed is CSF2; the disease is neuroblastoma.